Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor.
Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor.
复制标题
DOI：
--
复制
发表时间：
1988-12
期刊：
影响因子：
--
通讯作者：
Janice F. Sissom;Marsha L. Eigenbrodt;andJOHN C. Porter
中科院分区：
文献类型：
--
作者：
Janice F. Sissom;Marsha L. Eigenbrodt;andJOHN C. Porter
使用纯化的PRL受体单克隆抗体（PrR-7A）进行以下研究。当PRL受体在含有PrR-7A抗体或抗血青素单克隆抗体作为对照的亲和柱上进行层析时，PRL受体与含有PrR-7A抗体的柱结合，而不与含有对照抗体的柱结合。将溶解后的PRL受体与PrR-7A抗体孵育后，受体特异性结合降低52%。雌性小鼠用致癌物7,12-二甲基苯[a]蒽治疗，在随后的48周内每周用PrR-7A抗体或对照抗体治疗。在对照组中，13%的人患了乳腺癌，16%的人患了中度至重度导管内增生。用PrR-7A抗体处理的小鼠未发现乳腺癌，只有8%的小鼠出现中度至重度导管内增生。用PrR-7A或对照抗体治疗经垂体植入致高泌乳素血症的雄性小鼠。治疗7周后，PrR-7A抗体组小鼠的前列腺平均重量为8 +/- 1.1 mg（平均+/- SE），对照组小鼠的前列腺平均重量为27 +/- 3.6 mg。前列腺的蛋白质和DNA含量也有类似的差异。这些结果表明，PrR-7A抗体是针对PRL受体的，该抗体免疫可降低PRL依赖性乳腺肿瘤和瘤前导管增生的发生率，并可预防PRL诱导的前列腺增生。
Monoclonal antibody (PrR-7A) against purified PRL receptor was used in the following studies. When PRL receptor was chromatographed on affinity columns containing PrR-7A antibody or monoclonal antibody against hemocyanin, which served as a control, PRL receptor was bound to the column containing PrR-7A antibody, but not to the column containing control antibody. When solubilized PRL receptor was incubated with PrR-7A antibody, the specific binding of the receptor was reduced 52%. Female mice were treated with the carcinogen, 7,12-dimethylbenz[a]anthracene, and during the succeeding 48 weeks were treated weekly with PrR-7A antibody or control antibody. In the control group 13% developed mammary carcinomas, and 16% developed moderate-to-severe intraductal hyperplasia. No mammary carcinomas were found in the mice treated with PrR-7A antibody, and only 8% of the mice had moderate-to-severe intraductal hyperplasia. Male mice made hyperprolactinemic by implanted pituitary glands were treated weekly with PrR-7A or control antibody. After 7 weeks of treatment, the mean weight of the prostates of mice treated with PrR-7A antibody was 8 +/- 1.1 mg (mean +/- SE), and that of mice treated with control antibody was 27 +/- 3.6 mg. Similar differences were seen in the protein and DNA content of the prostates. These results indicate that PrR-7A antibody is directed against PRL receptor and that immunization with this antibody reduces the incidence of PRL-dependent mammary tumors and preneoplastic ductal hyperplasia and prevents PRL-induced hyperplasia of the prostate.